> Alnylam Pharmaceuticals has started dosing patients in a Phase I study of the RNAi therapy ALN-TTR01, which uses Tekmira's leading lipid nanoparticle delivery technology. Release > Thermo Fisher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results